;PMID: 8937721
;source_file_828.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..40] = [t:0..40]
;1)sentence:[e:46..154] = [t:46..154]
;2)section:[e:158..216] = [t:158..216]
;3)section:[e:220..284] = [t:220..284]
;4)sentence:[e:288..290] = [t:288..290]
;5)sentence:[e:291..457] = [t:291..457]
;6)sentence:[e:458..659] = [t:458..659]
;7)sentence:[e:660..662] = [t:660..662]
;8)sentence:[e:663..832] = [t:663..832]
;9)sentence:[e:833..905] = [t:833..905]
;10)sentence:[e:906..1052] = [t:906..1052]
;11)sentence:[e:1053..1187] = [t:1053..1187]
;12)sentence:[e:1188..1190] = [t:null]
;13)sentence:[e:1191..1406] = [t:1191..1406]
;14)sentence:[e:1407..1409] = [t:1407..1409]
;15)sentence:[e:1410..1544] = [t:1410..1544]
;16)sentence:[e:1545..1547] = [t:null]
;17)sentence:[e:1548..1724] = [t:1548..1724]
;18)sentence:[e:1726..1844] = [t:1726..1844]
;19)sentence:[e:1845..1847] = [t:1845..1847]
;20)sentence:[e:1848..1997] = [t:1848..1997]
;21)sentence:[e:1998..2000] = [t:null]
;22)sentence:[e:2001..2120] = [t:2001..2120]
;23)sentence:[e:2121..2259] = [t:2121..2259]
;24)sentence:[e:2261..2347] = [t:2261..2347]
;25)section:[e:2351..2395] = [t:2351..2395]
;Sentence Matching Errors
;ERROR_Different number of sections entity has 26 tree 23
;ERROR_Entity section missing treebank section[1188..1190]
;ERROR_Entity section missing treebank section[1545..1547]
;ERROR_Entity section missing treebank section[1998..2000]
;Token/POS Errors
;ERROR_Token in entity file but not tree[1188..1190] 3.
;ERROR_Token in entity file but not tree[1545..1547] 5.
;ERROR_Token in entity file but not tree[1998..2000] 7.

;section 0 Span:0..40
;Br J Pharmacol. 1996 Nov;119(6):1177-86.
(SEC
  (FRAG (NNP:[0..2] Br) (NNP:[3..4] J) (NNP:[5..14] Pharmacol) (.:[14..15] .)
        (CD:[16..20] 1996) (.:[21..29] Nov;119-LRB-) (CD:[29..31] 6-RRB-)
        (CD:[31..36] :1177) (HYPH:[36..37] -) (CD:[37..39] 86) (.:[39..40] .)))

;sentence 1 Span:46..154
;Mechanisms of L-NG nitroarginine/indomethacin-resistant relaxation in bovine
;and  porcine coronary arteries.
;[60..78]:substance:"L-NG nitroarginine"
;[79..91]:substance:"indomethacin"
(SENT
  (NP-HLN
    (NP (NNS:[46..56] Mechanisms))
    (PP (IN:[57..59] of)
      (NP
        (ADJP
          (NML
            (NML (NN:[60..64] L-NG) (NN:[65..78] nitroarginine))
            (SYM:[78..79] /)
            (NML (NN:[79..91] indomethacin)))
          (HYPH:[91..92] -) (JJ:[92..101] resistant))
        (NN:[102..112] relaxation)))
    (PP-LOC (IN:[113..115] in)
      (NP
        (NP (JJ:[116..122] bovine)
          (NML-1 (-NONE-:[122..122] *P*)))
        (CC:[123..126] and)
        (NP (JJ:[128..135] porcine)
          (NML-1 (JJ:[136..144] coronary) (NNS:[145..153] arteries)))))
    (.:[153..154] .)))

;section 2 Span:158..216
;Graier WF, Holzmann S, Hoebel BG, Kukovetz WR, Kostner GM.
(SEC
  (FRAG (NNP:[158..164] Graier) (NNP:[165..167] WF) (,:[167..168] ,)
        (NNP:[169..177] Holzmann) (NNP:[178..180] S,) (NNP:[181..187] Hoebel)
        (NNP:[188..190] BG) (,:[190..191] ,) (NNP:[192..200] Kukovetz)
        (NNP:[201..203] WR) (,:[203..204] ,) (DT:[205..212] Kostner)
        (NNP:[213..215] GM) (.:[215..216] .)))

;section 3 Span:220..284
;Department of Medical Biochemistry, University of Graz, Austria.
(SEC
  (FRAG (NNP:[220..230] Department) (IN:[231..233] of) (NNP:[234..241] Medical)
        (NNP:[242..254] Biochemistry) (,:[254..255] ,)
        (NNP:[256..266] University) (IN:[267..269] of) (NNP:[270..274] Graz)
        (,:[274..275] ,) (NNP:[276..283] Austria) (.:[283..284] .)))

;sentence 4 Span:288..290
;1.
(SENT
  (NP (LS:[288..290] 1.)))

;sentence 5 Span:291..457
;Coronary arteries from bovines (BCA) and pigs (PCA) were used for measuring 
;endothelium-dependent relaxation in the presence of L-NG nitroarginine and 
;indomethacin.
;[420..438]:substance:"L-NG nitroarginine"
;[444..456]:substance:"indomethacin"
(SENT
  (S
    (NP-SBJ-1
      (NP (JJ:[291..299] Coronary) (NNS:[300..308] arteries))
      (PP (IN:[309..313] from)
        (NP
          (NP (NNS:[314..321] bovines)
            (PRN (-LRB-:[322..323] -LRB-)
              (NP (NN:[323..326] BCA))
              (-RRB-:[326..327] -RRB-)))
          (CC:[328..331] and)
          (NP (NNS:[332..336] pigs)
            (PRN (-LRB-:[337..338] -LRB-)
              (NP (NN:[338..341] PCA))
              (-RRB-:[341..342] -RRB-))))))
    (VP (VBD:[343..347] were)
      (VP (VBN:[348..352] used)
        (NP-1 (-NONE-:[352..352] *))
        (PP-PRP (IN:[353..356] for)
          (S-NOM
            (NP-SBJ (-NONE-:[356..356] *))
            (VP (VBG:[357..366] measuring)
              (NP
                (NP
                  (ADJP (NN:[368..379] endothelium) (HYPH:[379..380] -)
                        (JJ:[380..389] dependent))
                  (NN:[390..400] relaxation))
                (PP (IN:[401..403] in)
                  (NP
                    (NP (DT:[404..407] the) (NN:[408..416] presence))
                    (PP (IN:[417..419] of)
                      (NP
                        (NP (NN:[420..424] L-NG) (NN:[425..438] nitroarginine))
                        (CC:[439..442] and)
                        (NP (NN:[444..456] indomethacin))))))))))))
    (.:[456..457] .)))

;sentence 6 Span:458..659
;As some compounds tested have been found to have an inhibitory  effect on
;autacoid-activated endothelial Ca2+ signalling, endothelium-dependent 
;relaxation was initiated with the Ca2+ ionophore A23187.
;[466..475]:substance:"compounds"
;[532..540]:substance:"autacoid"
;[563..567]:substance:"Ca2+"
;[637..641]:substance:"Ca2+"
;[642..651]:substance:"ionophore"
;[652..658]:substance:"A23187"
(SENT
  (S
    (SBAR-ADV (IN:[458..460] As)
      (S
        (NP-SBJ-1
          (NP (DT:[461..465] some) (NNS:[466..475] compounds))
          (VP (VBN:[476..482] tested)
            (NP (-NONE-:[482..482] *))))
        (VP (VBP:[483..487] have)
          (VP (VBN:[488..492] been)
            (VP (VBN:[493..498] found)
              (S
                (NP-SBJ-1 (-NONE-:[498..498] *))
                (VP (TO:[499..501] to)
                  (VP (VB:[502..506] have)
                    (NP
                      (NP (DT:[507..509] an) (JJ:[510..520] inhibitory)
                          (NN:[522..528] effect))
                      (PP (IN:[529..531] on)
                        (NP
                          (ADJP (NN:[532..540] autacoid) (HYPH:[540..541] -)
                                (VBN:[541..550] activated))
                          (NML (JJ:[551..562] endothelial)
                             (NN:[563..566] Ca2) (SYM:[566..567] +))
                          (NN:[568..578] signalling))))))))))))
    (,:[578..579] ,)
    (NP-SBJ-2
      (ADJP (NN:[580..591] endothelium) (HYPH:[591..592] -)
            (JJ:[592..601] dependent))
      (NN:[603..613] relaxation))
    (VP (VBD:[614..617] was)
      (VP (VBN:[618..627] initiated)
        (NP-2 (-NONE-:[627..627] *))
        (PP (IN:[628..632] with)
          (NP
            (NP (DT:[633..636] the)
              (NML (NN:[637..640] Ca2) (SYM:[640..641] +))
              (NN:[642..651] ionophore))
            (NP (NN:[652..658] A23187))))))
    (.:[658..659] .)))

;sentence 7 Span:660..662
;2.
(SENT
  (NP (LS:[660..662] 2.)))

;sentence 8 Span:663..832
;The common compounds  for modulating arachidonic acid release/pathway,
;mepacrine and econazole only  inhibited L-NG nitroarginine-resistant
;relaxation in BCA not in PCA.
;[674..683]:substance:"compounds"
;[700..716]:substance:"arachidonic acid"
;[734..743]:substance:"mepacrine"
;[748..757]:substance:"econazole"
;[774..792]:substance:"L-NG nitroarginine"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (DT:[663..666] The) (JJ:[667..673] common)
            (NNS:[674..683] compounds))
        (PP (IN:[685..688] for)
          (S-NOM
            (NP-SBJ (-NONE-:[688..688] *))
            (VP (VBG:[689..699] modulating)
              (NP (JJ:[700..711] arachidonic)
                (NML (NN:[712..716] acid) (NN:[717..724] release))
                (SYM:[724..725] /) (NN:[725..732] pathway))))))
      (,:[732..733] ,)
      (NP (NN:[734..743] mepacrine) (CC:[744..747] and)
          (NN:[748..757] econazole)))
    (ADVP (RB:[758..762] only))
    (VP
      (VP (VBD:[764..773] inhibited)
        (NP
          (ADJP
            (NML (NN:[774..778] L-NG) (NN:[779..792] nitroarginine))
            (HYPH:[792..793] -) (JJ:[793..802] resistant))
          (NN:[803..813] relaxation))
        (PP-LOC=1 (IN:[814..816] in)
          (NP (NN:[817..820] BCA))))
      (VP (RB:[821..824] not)
        (PP-LOC=1 (IN:[825..827] in)
          (NP (NN:[828..831] PCA)))))
    (.:[831..832] .)))

;sentence 9 Span:833..905
;In  contrast, proadifen (SKF 525A) diminished relaxation in BCA and PCA.
;[847..856]:substance:"proadifen"
;[858..866]:substance:"SKF 525A"
(SENT
  (S
    (PP (IN:[833..835] In)
      (NP (NN:[837..845] contrast)))
    (,:[845..846] ,)
    (NP-SBJ
      (NP (NN:[847..856] proadifen))
      (NP (-LRB-:[857..858] -LRB-)
         (NN:[858..861] SKF) (NN:[862..866] 525A)
        (-RRB-:[866..867] -RRB-)))
    (VP (VBD:[868..878] diminished)
      (NP (NN:[879..889] relaxation))
      (PP-LOC (IN:[890..892] in)
        (NP (NN:[893..896] BCA) (CC:[897..900] and) (NN:[901..904] PCA))))
    (.:[904..905] .)))

;sentence 10 Span:906..1052
;Mepacrine  and proadifen inhibited Hoe-234-initiated relaxation in BCA and
;PCA, while  econazole only inhibited Hoe 234-induced relaxation in PCA.
;[906..915]:substance:"Mepacrine"
;[921..930]:substance:"proadifen"
;[941..948]:substance:"Hoe-234"
;[993..1002]:substance:"econazole"
;[1018..1025]:substance:"Hoe 234"
(SENT
  (S
    (NP-SBJ (NN:[906..915] Mepacrine) (CC:[917..920] and)
            (NN:[921..930] proadifen))
    (VP (VBD:[931..940] inhibited)
      (NP
        (ADJP (NN:[941..948] Hoe-234) (HYPH:[948..949] -)
              (VBN:[949..958] initiated))
        (NN:[959..969] relaxation))
      (PP-LOC (IN:[970..972] in)
        (NP (NN:[973..976] BCA) (CC:[977..980] and) (NN:[981..984] PCA)))
      (,:[984..985] ,)
      (SBAR-ADV (IN:[986..991] while)
        (S
          (NP-SBJ (NN:[993..1002] econazole))
          (ADVP (RB:[1003..1007] only))
          (VP (VBD:[1008..1017] inhibited)
            (NP
              (ADJP
                (NML (NN:[1018..1021] Hoe) (CD:[1022..1025] 234))
                (HYPH:[1025..1026] -) (VBN:[1026..1033] induced))
              (NN:[1034..1044] relaxation))
            (PP-LOC (IN:[1045..1047] in)
              (NP (NN:[1048..1051] PCA)))))))
    (.:[1051..1052] .)))

;sentence 11 Span:1053..1187
;Due to the multiple  effects of these compounds, caution is necessary in the
;interpretation of  results obtained with these compounds.
;[1091..1100]:substance:"compounds"
;[1177..1186]:substance:"compounds"
(SENT
  (S
    (PP (JJ:[1053..1056] Due)
      (PP (TO:[1057..1059] to)
        (NP
          (NP (DT:[1060..1063] the) (JJ:[1064..1072] multiple)
              (NNS:[1074..1081] effects))
          (PP (IN:[1082..1084] of)
            (NP (DT:[1085..1090] these) (NNS:[1091..1100] compounds))))))
    (,:[1100..1101] ,)
    (NP-SBJ (NN:[1102..1109] caution))
    (VP (VBZ:[1110..1112] is)
      (ADJP-PRD (JJ:[1113..1122] necessary))
      (PP (IN:[1123..1125] in)
        (NP
          (NP (DT:[1126..1129] the) (NN:[1130..1144] interpretation))
          (PP (IN:[1145..1147] of)
            (NP
              (NP (NNS:[1149..1156] results))
              (VP (VBN:[1157..1165] obtained)
                (NP (-NONE-:[1165..1165] *))
                (PP-MNR (IN:[1166..1170] with)
                  (NP (DT:[1171..1176] these) (NNS:[1177..1186] compounds)))))))))
    (.:[1186..1187] .)))

(ORPH 3.)

;sentence 12 Span:1191..1406
;The inhibitor of Ca(2+)-activated K+  channels, apamin, strongly attenuated
;A23187-induced L-NG  nitroarginine-resistant relaxation in BCA while apamin
;did not affect L-NG  nitroarginine-resistant relaxation in PCA.
;[1195..1204]:substance:"inhibitor"
;[1208..1214]:substance:"Ca(2+)"
;[1225..1227]:substance:"K+"
;[1239..1245]:substance:"apamin"
;[1267..1273]:substance:"A23187"
;[1282..1301]:substance:"L-NG  nitroarginine"
;[1336..1342]:substance:"apamin"
;[1358..1377]:substance:"L-NG  nitroarginine"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (DT:[1191..1194] The) (NN:[1195..1204] inhibitor))
        (PP (IN:[1205..1207] of)
          (NP
            (ADJP (NN:[1208..1214] Ca-LRB-2+-RRB-) (HYPH:[1214..1215] -)
                  (VBN:[1215..1224] activated))
            (NML (NN:[1225..1226] K) (SYM:[1226..1227] +))
            (NNS:[1229..1237] channels))))
      (,:[1237..1238] ,)
      (NP (NN:[1239..1245] apamin)))
    (,:[1245..1246] ,)
    (ADVP (RB:[1247..1255] strongly))
    (VP (VBD:[1256..1266] attenuated)
      (NP
        (ADJP (NN:[1267..1273] A23187) (HYPH:[1273..1274] -)
              (VBN:[1274..1281] induced))
        (ADJP
          (NML (NN:[1282..1286] L-NG) (NN:[1288..1301] nitroarginine))
          (HYPH:[1301..1302] -) (JJ:[1302..1311] resistant))
        (NN:[1312..1322] relaxation))
      (PP-LOC (IN:[1323..1325] in)
        (NP (NN:[1326..1329] BCA)))
      (SBAR-ADV (IN:[1330..1335] while)
        (S
          (NP-SBJ (NN:[1336..1342] apamin))
          (VP (VBD:[1343..1346] did) (RB:[1347..1350] not)
            (VP (VB:[1351..1357] affect)
              (NP
                (ADJP
                  (NML (NN:[1358..1362] L-NG) (NN:[1364..1377] nitroarginine))
                  (HYPH:[1377..1378] -) (JJ:[1378..1387] resistant))
                (NN:[1388..1398] relaxation))
              (PP-LOC (IN:[1399..1401] in)
                (NP (NN:[1402..1405] PCA))))))))
    (.:[1405..1406] .)))
;ERROR_Orphan Text from Tree File[1187..1191] 3.

;sentence 13 Span:1407..1409
;4.
(SENT
  (NP (LS:[1407..1409] 4.)))

;sentence 14 Span:1410..1544
;Pertussis toxin blunted L-NG  nitroarginine-resistant relaxation in BCA,
;while relaxation of PCA was not  affected by pertussis toxin.
;[1410..1425]:substance:"Pertussis toxin"
;[1434..1453]:substance:"L-NG  nitroarginine"
;[1528..1543]:substance:"pertussis toxin"
(SENT
  (S
    (NP-SBJ (NN:[1410..1419] Pertussis) (NN:[1420..1425] toxin))
    (VP (VBD:[1426..1433] blunted)
      (NP
        (ADJP
          (NML (NN:[1434..1438] L-NG) (NN:[1440..1453] nitroarginine))
          (HYPH:[1453..1454] -) (JJ:[1454..1463] resistant))
        (NN:[1464..1474] relaxation))
      (PP-LOC (IN:[1475..1477] in)
        (NP (NN:[1478..1481] BCA)))
      (,:[1481..1482] ,)
      (SBAR-ADV (IN:[1483..1488] while)
        (S
          (NP-SBJ-1
            (NP (NN:[1489..1499] relaxation))
            (PP (IN:[1500..1502] of)
              (NP (NN:[1503..1506] PCA))))
          (VP (VBD:[1507..1510] was) (RB:[1511..1514] not)
            (VP (VBN:[1516..1524] affected)
              (NP-1 (-NONE-:[1524..1524] *))
              (PP (IN:[1525..1527] by)
                (NP-LGS (NN:[1528..1537] pertussis) (NN:[1538..1543] toxin))))))))
    (.:[1543..1544] .)))

(ORPH 5.)

;sentence 15 Span:1548..1724
;Thiopentone sodium inhibited endothelial  cytochrome P450 epoxygenase (EPO)
;in PCA but not in BCA, while L-NG  nitroarginine-resistant relaxation of BCA
;and PCA were unchanged.
;[1548..1566]:substance:"Thiopentone sodium"
;[1590..1617]:cyp450:"cytochrome P450 epoxygenase"
;[1619..1622]:cyp450:"EPO"
;[1653..1672]:substance:"L-NG  nitroarginine"
(SENT
  (S
    (NP-SBJ (NN:[1548..1559] Thiopentone) (NN:[1560..1566] sodium))
    (VP
      (VP (VBD:[1567..1576] inhibited)
        (NP (JJ:[1577..1588] endothelial)
          (NML (NN:[1590..1600] cytochrome) (NN:[1601..1605] P450))
          (NML
            (NML (NN:[1606..1617] epoxygenase))
            (NML (-LRB-:[1618..1619] -LRB-) (NN:[1619..1622] EPO)
                 (-RRB-:[1622..1623] -RRB-))))
        (PP-LOC=1 (IN:[1624..1626] in)
          (NP (NN:[1627..1630] PCA))))
      (CC:[1631..1634] but)
      (VP (RB:[1635..1638] not)
        (PP-LOC=1 (IN:[1639..1641] in)
          (NP (NN:[1642..1645] BCA))))
      (,:[1645..1646] ,)
      (SBAR-ADV (IN:[1647..1652] while)
        (S
          (NP-SBJ
            (NP
              (ADJP
                (NML (NN:[1653..1657] L-NG) (NN:[1659..1672] nitroarginine))
                (HYPH:[1672..1673] -) (JJ:[1673..1682] resistant))
              (NN:[1683..1693] relaxation))
            (PP (IN:[1694..1696] of)
              (NP (NN:[1697..1700] BCA) (CC:[1701..1704] and)
                  (NN:[1705..1708] PCA))))
          (VP (VBD:[1709..1713] were)
            (ADJP-PRD (JJ:[1714..1723] unchanged))))))
    (.:[1723..1724] .)))
;ERROR_Orphan Text from Tree File[1544..1548] 5.

;sentence 16 Span:1726..1844
;Protoporphyrine IX inhibited EPO in BCA and PCA and abolished L-NG 
;nitroarginine-resistant relaxation of BCA not PCA.
;[1726..1744]:substance:"Protoporphyrine IX"
;[1755..1758]:cyp450:"EPO"
;[1788..1807]:substance:"L-NG  nitroarginine"
(SENT
  (S
    (NP-SBJ (NN:[1726..1741] Protoporphyrine) (CD:[1742..1744] IX))
    (VP
      (VP (VBD:[1745..1754] inhibited)
        (NP (NN:[1755..1758] EPO))
        (PP-LOC (IN:[1759..1761] in)
          (NP (NN:[1762..1765] BCA) (CC:[1766..1769] and) (NN:[1770..1773] PCA))))
      (CC:[1774..1777] and)
      (VP
        (VP (VBD:[1778..1787] abolished)
          (NP
            (NP
              (ADJP
                (NML (NN:[1788..1792] L-NG) (NN:[1794..1807] nitroarginine))
                (HYPH:[1807..1808] -) (JJ:[1808..1817] resistant))
              (NN:[1818..1828] relaxation))
            (PP (IN:[1829..1831] of)
              (NP=1 (NN:[1832..1835] BCA)))))
        (VP (RB:[1836..1839] not)
          (NP=1 (NN:[1840..1843] PCA)))))
    (.:[1843..1844] .)))

;sentence 17 Span:1845..1847
;6.
(SENT
  (NP (LS:[1845..1847] 6.)))

;sentence 18 Span:1848..1997
;An EPO-derived compound,  11,12-epoxy-eicosatrienoic acid (11,12-EET) yielded
;significant relaxation in  BCA and PCA in three out of six experiments.
;[1851..1871]:substance:"EPO-derived compound"
;[1874..1905]:substance:"11,12-epoxy-eicosatrienoic acid"
;[1907..1916]:substance:"11,12-EET"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1848..1850] An)
        
        (ADJP (NN:[1851..1854] EPO) (HYPH:[1854..1855] -)
              (VBN:[1855..1862] derived))
        (NN:[1863..1871] compound))
      (,:[1871..1872] ,)
      (NP
        (NP (JJ:[1874..1900] 11,12-epoxy-eicosatrienoic) (NN:[1901..1905] acid))
        (NP (-LRB-:[1906..1907] -LRB-) (NN:[1907..1916] 11,12-EET)
            (-RRB-:[1916..1917] -RRB-))))
    (VP (VBD:[1918..1925] yielded)
      (NP (JJ:[1926..1937] significant) (NN:[1938..1948] relaxation))
      (PP-LOC (IN:[1949..1951] in)
        (NP (NN:[1953..1956] BCA) (CC:[1957..1960] and) (NN:[1961..1964] PCA)))
      (PP (IN:[1965..1967] in)
        (NP
          (NP (CD:[1968..1973] three))
          (PP (IN:[1974..1977] out)
            (PP (IN:[1978..1980] of)
              (NP (CD:[1981..1984] six) (NNS:[1985..1996] experiments)))))))
    (.:[1996..1997] .)))

(ORPH 7.)

;sentence 19 Span:2001..2120
;These findings suggest that L-NG  nitroarginine-resistant relaxation in BCA
;and PCA constitutes two distinct  pathways.
;[2029..2048]:substance:"L-NG  nitroarginine"
(SENT
  (S
    (NP-SBJ (DT:[2001..2006] These) (NNS:[2007..2015] findings))
    (VP (VBP:[2016..2023] suggest)
      (SBAR (IN:[2024..2028] that)
        (S
          (NP-SBJ
            (NP
              (ADJP
                (NML (NN:[2029..2033] L-NG) (NN:[2035..2048] nitroarginine))
                (HYPH:[2048..2049] -) (JJ:[2049..2058] resistant))
              (NN:[2059..2069] relaxation))
            (PP-LOC (IN:[2070..2072] in)
              (NP (NN:[2073..2076] BCA) (CC:[2077..2080] and)
                  (NN:[2081..2084] PCA))))
          (VP (VBZ:[2085..2096] constitutes)
            (NP (CD:[2097..2100] two) (JJ:[2101..2109] distinct)
                (NNS:[2111..2119] pathways))))))
    (.:[2119..2120] .)))
;ERROR_Orphan Text from Tree File[1997..2001] 7.

;sentence 20 Span:2121..2259
;In BCA, activation of Ca(2+)-activated K+ channels via a 
;pertussis-toxin-sensitive G protein and EPO-derived compounds might be
;involved.
;[2143..2149]:substance:"Ca(2+)"
;[2160..2162]:substance:"K+"
;[2179..2214]:substance:"pertussis-toxin-sensitive G protein"
;[2219..2240]:substance:"EPO-derived compounds"
(SENT
  (S
    (PP-LOC (IN:[2121..2123] In)
      (NP (NN:[2124..2127] BCA)))
    (,:[2127..2128] ,)
    (NP-SBJ-1
      (NP (NN:[2129..2139] activation))
      (PP (IN:[2140..2142] of)
        (NP
          (ADJP (NN:[2143..2149] Ca-LRB-2+-RRB-) (HYPH:[2149..2150] -)
                (VBN:[2150..2159] activated))
          (NML (NN:[2160..2161] K) (SYM:[2161..2162] +))
          (NNS:[2163..2171] channels)))
      (PP (IN:[2172..2175] via)
        (NP
          (NP (DT:[2176..2177] a)
            
            (ADJP
              (NML (NN:[2179..2188] pertussis) (HYPH:[2188..2189] -)
                   (NN:[2189..2194] toxin))
              (HYPH:[2194..2195] -) (JJ:[2195..2204] sensitive))
            (NN:[2205..2206] G) (NN:[2207..2214] protein))
          (CC:[2215..2218] and)
          (NP
            (ADJP (NN:[2219..2222] EPO) (HYPH:[2222..2223] -)
                  (VBN:[2223..2230] derived))
            (NNS:[2231..2240] compounds)))))
    (VP (MD:[2241..2246] might)
      (VP (VB:[2247..2249] be)
        (VP (VBN:[2250..2258] involved)
          (NP-1 (-NONE-:[2258..2258] *)))))
    (.:[2258..2259] .)))

;sentence 21 Span:2261..2347
;In PCA, no selective inhibition of L-NG nitroarginine-resistant relaxation
;was  found.
;[2296..2314]:substance:"L-NG nitroarginine"
(SENT
  (S
    (PP-LOC (IN:[2261..2263] In)
      (NP (NN:[2264..2267] PCA)))
    (,:[2267..2268] ,)
    (NP-SBJ-1
      (NP (DT:[2269..2271] no) (JJ:[2272..2281] selective)
          (NN:[2282..2292] inhibition))
      (PP (IN:[2293..2295] of)
        (NP
          (ADJP
            (NML (NN:[2296..2300] L-NG) (NN:[2301..2314] nitroarginine))
            (HYPH:[2314..2315] -) (JJ:[2315..2324] resistant))
          (NN:[2325..2335] relaxation))))
    (VP (VBD:[2336..2339] was)
      (VP (VBN:[2341..2346] found)
        (NP-1 (-NONE-:[2346..2346] *))))
    (.:[2346..2347] .)))

;section 22 Span:2351..2395
;PMID: 8937721 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2351..2355] PMID) (::[2355..2356] :) (CD:[2357..2364] 8937721)
        (-LRB-:[2365..2366] -LSB-) (NNP:[2366..2372] PubMed)
        (HYPH:[2373..2374] -) (NN:[2375..2382] indexed) (IN:[2383..2386] for)
        (NNP:[2387..2394] MEDLINE) (-RRB-:[2394..2395] -RSB-)))
